SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant Stake in Celldex Therapeutics

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a continued beneficial ownership of 7.3% of Celldex Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson jointly filed an Amendment No. 5 to Schedule 13G, reporting their beneficial ownership in Celldex Therapeutics Inc.
• As of December 31, 2024, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 4,857,668 shares of common stock.
• This represents 7.3% of the total outstanding common stock of Celldex Therapeutics Inc.
• FMR LLC holds sole voting power over 4,855,957 shares and sole dispositive power over 4,857,668 shares.
• Abigail P. Johnson holds sole dispositive power over 4,857,668 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 5), indicating a continued passive stake. It does not contain new operational or financial performance information that would significantly alter sentiment.

Positives

• A major institutional investor, FMR LLC, and its affiliates, along with Abigail P. Johnson, maintain a significant beneficial ownership stake of 7.3% in Celldex Therapeutics Inc., indicating continued confidence or a long-term investment strategy.
• The filing confirms the passive nature of the investment, stating the shares are held in the ordinary course of business and not for control purposes, which can provide stability.

Risks

• The filing explicitly states that the securities are not held for the purpose of changing or influencing the control of the issuer, which means the reporting persons are passive investors and will not actively seek to influence company management or strategy.

Future Outlook

NA

Industry Context

FMR LLC is a prominent global asset management firm, and its significant stake in Celldex Therapeutics Inc., a biotechnology company, reflects institutional interest in the biotech sector. Such filings are routine disclosures for large passive investors.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed as a vote of confidence or stability from a major investor.

Key Dates

Keywords

Celldex Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment, biotech, pharmaceutical